Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...
Donanemab could be the second amyloid antibody drug approved to treat early-stage Alzheimer’s disease. The drug slowed ...
A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
There isn’t a cure for Alzheimer’s disease, the most common form of dementia in the U.S., but a third treatment for the ...
The new weight-loss drug company emerged from stealth with big plans to take on obesity drugs like Wegovy and Zepbound.
President Joe Biden and former President Donald Trump have seemingly found one issue they can agree on: Drug costs are too high. Each is crediting himself with price-busting policy successes that ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) ...
ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...